文献速递浆细胞疾病

大型荟萃分析确立MRD阴性在多发性骨髓瘤长期生存结局中的作用

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
PubMed 文献 · Blood Adv · 2020-01-01

该研究通过系统文献综述和荟萃分析评估了微小残留病(MRD)对多发性骨髓瘤(MM)患者无进展生存期(PFS)和总生存期(OS)的预后价值。结果显示,与MRD阳性相比,达到MRD阴性可改善PFS(HR 0.33;95%CI 0.29-0.37;95%CI 0.39-0.51;

要点

  • MRD阴性显著改善PFS(HR 0.33)和OS(HR 0.45),且不受疾病阶段、检测方法等因素影响。
  • MRD阴性可作为多发性骨髓瘤治疗终点和生存替代指标。
  • 该荟萃分析支持将MRD纳入治疗策略开发。

核心结论

  • MRD阴性是多发性骨髓瘤PFS和OS的相关替代指标,支持将其作为治疗终点。

主要发现

  • MRD阴性生存获益不受疾病设置(新诊断或复发/难治)、MRD灵敏度阈值、细胞遗传学风险、MRD评估方法、MRD检测时临床缓解深度、维持治疗前及维持治疗开始后12个月评估的影响。

临床怎么用

  • 可将MRD阴性作为多发性骨髓瘤治疗终点和生存替代指标,用于治疗策略开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database. Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan-Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001). MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy. The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020. PMID: 33284948. doi:10.1182/bloodadvances.2020002827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。